Roche wins first-line approval for PI3K inhibitor combo in breast cancer
The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer patients.
The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer patients.
What's Your Reaction?
